Compare CVS Health Corp (CVS) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Eni SpA — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Eni SpA trades at $55.64 (market cap $78.10B). The key difference: CVS Health Corp is the larger of the two by market cap, and Eni SpA pays the higher dividend (4.52%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Eni SpA for 53 Days on average.
| CVS | E | |
|---|---|---|
Market Cap | $112.49B | $78.10B |
Volume | 8,467,392 | 296,516 |
Sector | Health | Energy |
52-Week High | $110.60 | $57.61 |
52-Week Low | $70.08 | $34.03 |
Typical Hold Time | 83 Days | 53 Days |
Enterprise Value | $174.83B | $102.75B |
Dividend Yield | 3.02% | 4.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Eni (E) trades at $55.62, up 1.96% today, amid a bearish technical signal. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97% in 2026. The company maintains solid cash flow and a low P/E of 12.53. Recent news highlights expansion in humanoid robotics, LNG projects in Argentina, and fuel discounts in Italy, indicating strategic diversification and customer support initiatives.
The outlook is mixed; valuation appears attractive with low multiples, and analyst consensus leans hold (61.53%). However, declining revenue, recent earnings misses, and bearish technicals pose near-term risks. Upside depends on execution of new projects and stabilization of energy markets, while volatility in oil prices remains a key sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
